Desjardins A., Quinn J.A., Rich J.N., Vredenburgh J.J., Sathornsumetee S., Gururangan S., Friedman A.H., Berg W., Egorin M.J., Salvado A., Friedman H.S., Reardon D.A. A phase I trial of imatinib (GLEEVEC), hydroxyurea and RAD001 for patients with recurrent malignant glioma. Neuro-Oncology.
2006.
8
Journal Name : Neuro-Oncology Source : ISI
132.
Desjardins A., Reardon D.A., Quinn J.A., Rich J.N., Vredenburgh J.J., Sathornsumetee S., Salvado A., Friedman H.S. Phase II trial of imatinib mesylate and hydroxyurea for grade III malignant gliomas. Journal of Clinical Oncology.
2006.
24
76S-76S.
Journal Name : Journal of Clinical Oncology Source : ISI
133.
Desjardins A., Vredenburgh J., Quinn J., Rich J., Sathornsumetee S., Friedman A., Reardon D., Friedman H. Combination of bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and temozolomide or irinotecan as an upfront treatment in patients with malignant glioma: Study of cases. Neuro-Oncology.
2006.
8
Journal Name : Neuro-Oncology Source : ISI
134.
Desjardins, A; Vredenburgh, J; Quinn, J; Rich, J; Sathornsumetee, S; Gururangan, S; Friedman, A; Reardon, D; Friedman, H. Combination of bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and chemotherapy for recurrent malignant glioma patients: Series of cases. Neuro-Oncology.
2006.
8
Journal Name : Neuro-Oncology Source : ISI
135.
Di Legge S., Saposnik G., Nilanont Y., Hachinski V. Neglecting the difference: Does right or left matter in stroke outcome after thrombolysis?. Stroke.
2006.
37
(8):
2066-2069.
Journal Name : Stroke Source : Scopus
